Heron Therapeutics, Inc. (HRTX) Earnings Call Transcript & Summary

August 14, 2023

NASDAQ US Health Care Biotechnology earnings 28 min

Earnings Call Speaker Segments

Jeff Cohn

executive
#1

Thanks, Krista, and welcome everyone on this Wednesday afternoon. We're glad each of you could join this Heron Therapeutics earnings call, during which we will review our financial performance for the second quarter, which ended on June 30, 2023. With me from Heron today are Craig Collard, who serves as our Chief Executive Officer; Ira Duarte, our Executive Vice President and Chief Financial Officer; and Bill Forbes, our Executive Vice President and Chief Development Officer. For those of you listening via the conference call, slides can be viewed through the webcast, and after today's call concludes, they will also be posted on the Investor Relations section of our website. Before we begin, let me take a moment to remind everyone that forward-looking statements will be made by the company during this call. Keep in mind that anything we say which isn't a historical fact is a forward-looking statement. That includes comments about projections, expectations, plans, beliefs, and future performance for the company — all of which qualify as forward-looking under the safe harbor provision of the Private Securities Litigation Reform Act of 1995. Statements like these are based on judgment and analysis as of today's call, and they carry a number of significant risks and uncertainties that might make actual results differ materially from what those forward-looking statements describe. Details about the dangers and unknowns connected to the predictive remarks shared during this call and webcast can be found in the safe harbor notice included in today's press release, as well as in Heron's periodic public submissions to the SEC. Unless the law demands it, Heron takes on no duty to revise these predictive remarks so they mirror later occurrences or real results, and has no plan to do so. Having said that, I'll now pass the call to Chief Executive Officer Craig Collard.

Craig Collard

executive
#2

Appreciate that, Jeff. Hello, everyone, and thanks for being with us this afternoon for our earnings call covering the second quarter of 2023. It's my pleasure to walk you through several important things that have happened since we last spoke. Our people have been putting in serious effort, and I'm eager to give you updates that, in our view, will set Heron on a path to becoming a profitable business with rising revenues — among them progress on reducing costs, on our financing work, and on shifts within our executive management team, plus news about where things stand in our pending Hatch-Waxman ANDA patent litigation. During my initial earnings call as Heron's CEO, I noted that I'd been in the role for just 4 weeks, and the bulk of that period went toward evaluating the business and figuring out where quick improvements were possible. Assessing the executive leadership and putting the right changes in place was the initial step. Those changes are done, and today we have a leaner organization, with a new CFO, a Head of Development, a Head of Supply and Vendor Management, and fresh leadership in sales and marketing for the acute side of the business. I'm delighted to report that the new team has implemented a cost-reduction initiative successfully. By analyzing carefully and planning strategically, we pinpointed places to streamline operations and boost efficiencies. Across the coming 3 years, we anticipate realizing an impressive cash savings of roughly $75 million; this effort shows our commitment to fiscal responsibility and our dedication to optimizing resources for sustained growth. Beyond the cost-cutting steps, we strengthened the balance sheet by finishing a $30 million equity financing involving some of our biggest shareholders, and also by closing on a working capital facility of up to $50 million. Given our present operational plan, we anticipate this gives the company sufficient capital to reach profitability. This accomplishment highlights the trust our investors and partners place in our business strategy and in the growth potential of our products. We remain in the early phases of remaking Heron into a commercially focused company with efficient operations. The changes made this quarter are significant and have clearly improved the business while establishing a solid foundation for the future. The following phase of improvements will center on maximizing the growth potential of every one of our products across both the acute care and oncology sides of the business. Even amid this recent period of organizational change, the company continues to see product growth. We expect that to improve dramatically as we roll out new strategic plans going forward; now let me turn to some product highlights from the quarter; on the oncology side of the business, Q2 net product sales combined for CINVANTI and SUSTOL came to $27.3 million, which rose from $25.1 million for the same period in 2022. We also grew combined sales by 6% quarter-over-quarter. We're happy to restate the guidance we've given for the oncology franchise — net product sales of $99 million to $103 million across the whole of 2023. Also, we recently got a favorable result at the Markman hearing in the Hatch-Waxman ANDA litigation we have pending against Fresenius, where we're seeking to enforce our CINVANTI patents. That outcome pleases us, and we will keep enforcing and defending our patent portfolio aggressively. Now turning to the acute care portion of the business, with ZYNRELEF and APONVIE. On that side too, we keep seeing product growth, despite the fact that many of the changes we've planned are not yet in place. After we complete a lot of the initiatives aimed at strengthening the fundamentals of the way we run our business, our plan is to then proceed with certain transformational initiatives. ZYNRELEF net product sales during the quarter came to $4.2 million, versus $2.5 million in the same period of 2022. Unit growth from one quarter to the next was 11%. APONVIE net product sales during the quarter reached $300,000. APONVIE became commercially available in the U.S. on March 6, 2023. Throughout this launch phase, some customers are giving us very positive feedback because of APONVIE's unique clinical value. In fact, a number of hospital systems have already adopted it for all moderate/severe patients, and many others are currently scheduled for system-wide review. The coming phase of business improvement will center on product growth and getting the most value from our assets; where ZYNRELEF is concerned, we have 3 key initiatives underway to expand our business, among them our filed sNDA, the vial access needle, or VAN, and a prefilled syringe. ZYNRELEF is a unique product offering true 72-hour pain relief. It also carries pass-through reimbursement status, which lets our product be reimbursed separately outside of the surgical bundle in hospitals as well as ASCs. Each of these product improvements and attributes forms part of the new overall company and product strategy and ought to have a dramatic impact on our growth over the coming several years. This growth won't happen overnight, but our products have a great clinical profile, excellent reimbursement status, and with the right commercial plan, we should start to see massive improvement that will ultimately lead the company to profitability. As for the sNDA for our label expansion for ZYNRELEF, the FDA recently informed us of a 3-month extension of our PDUFA date, from October 23, 2023 to January 23, 2024. The division learned of our time line for some new nonclinical data the company was completing, and in the spirit of cooperation, we agreed to submit this new data to the division. The division deemed the submission a major amendment to our sNDA and therefore extended the review period by 3 months. To wrap up, the past quarter has been marked by significant accomplishments and strategic moves that will undoubtedly shape the trajectory of our company. Getting our cost-cutting programs up and running well, locking in both debt and equity funding, the good result from the CINVANTI Markman hearing, plus bringing in a stronger executive leadership group — all of that puts us in a place to keep succeeding and expanding. This business won't change overnight, of course, yet 2023 is going to be a turnaround year for Heron. We appreciate you sticking with us and backing the company while we work through this transition. At this point I'll hand the call to Ira Duarte, our CFO. Go ahead, Ira.

Ira Duarte

executive
#3

Appreciate that, Craig. For Q2 of 2023, our net revenues across all products came to $31.8 million, versus $27.6 million during the same quarter in 2022 — that works out to growth of 15% over that comparable span. When we look at the opening 6 months of 2023, product net revenues reached $61.4 million, up against $51.1 million for 2022, which equals a 20% rise. Turning to our acute care franchise, net revenues came in at $4.5 million and $8.3 million for the 3-month and 6-month periods that ended June 30, 2023, respectively — both up from $2.5 million and $3.5 million, respectively, during the matching stretch of 2022. As for oncology care franchise net product sales, those stood at $27.3 million and $53.1 million for the 3 and 6 months that ended June 30, 2023, respectively, climbing from $25.1 million and $47.5 million, respectively, for the equivalent period a year earlier. Product gross profit landed at $11.6 million for the quarter and $24.4 million across the 6 months that ended June 30, 2023, which represents 36.5% and 40% of net revenue, respectively; those margins took a hit because of a ZYNRELEF inventory write-off during both Q1 and Q2 of 2023. It's our belief that these margins will get better and level out as we make our way through a portion of that ZYNRELEF inventory. On top of that, we have several initiatives in progress — ones we'll talk about on upcoming earnings calls — that ought to deliver a strongly favorable effect on costs going forward. SG&A expense for Q2 and the 6 months that ended June 30, 2023, came to $36.4 million and $68.4 million, respectively, against $32.1 million and $64.1 million for the equivalent period of 2022, with that rise mostly driven by the reduction in force we announced in June 2023. Research and development expenses totaled $17.6 million and $31.4 million in Q2 and the 6 months that ended June 30, 2023, versus $28.8 million and $70.9 million during the comparable period of 2022. That lower spend mostly stemmed from reduced costs tied to ZYNRELEF, since production scale up, validation activities and raw materials qualifications all wrapped up in 2022; beyond that, personnel and related costs overall came down thanks to the reduction in force put in place in June 2022. We're confident we can keep cutting costs in this area going forward as we keep boosting efficiency. The operating loss for the quarter was $42.4 million, compared with $49.5 million in Q2 2022, while the net loss came to $42.1 million for Q2 2023 and $56.4 million for the comparable period in 2022. Now looking at the total year-to-date net loss. For 2023, that's a net loss of $74.8 million, compared with $120.2 million in the comparable period of 2022. On our balance sheet as of the end of June 30, 2023, cash and short-term investment balance sits at $33.2 million. That said, as Craig noted in his earlier remarks, we completed the capital raise of roughly $30 million in July 2023, along with a working capital facility of up to $50 million in August 2023. When you put these funding arrangements together with what we're doing to cut costs, we're set up to grow down the road and to move toward profitability. Craig, over to you.

Craig Collard

executive
#4

Thanks, Ira. Operator, at this time, we'd like to open the line for questions.

Serge Belanger

analyst
#5

We've got a few things to ask. The first is about reaching profitability. In the past, I believe you mentioned a late 2024 timeline — does that still hold? Or has it shifted because of the regulatory delay with ZYNRELEF? And perhaps you could walk through the assumptions behind how we arrive there. Then, second, on that regulatory delay for ZYNRELEF, could you describe what you anticipate the label expansion might look like after approval?

Craig Collard

executive
#6

Serge, appreciate the question. On profitability, as we've stated before, our belief is that we would reach profitability in late 2024. The key point here, based on the money we've raised, is that we don't anticipate needing to raise additional monies to reach that point. That forecast was built without any upside from the sNDA for the VAN or anything of that nature. So it's really just a trend forecast for how the product was performing. With the cost-reduction efforts we've made, we can reach profitability within that time frame. Some upside could come from certain things we're doing. Again, assuming we get the label expansion, we're anticipating — assuming some of the things we implement will positively impact ZYNRELEF when those types of things happen, and APONVIE as well. So from that standpoint, that's how we're getting to profitability into '24. On the sNDA and the expansion, I'd like to — Bill Forbes is here with us in the room, and I'd like maybe him to speak in a little bit more detail around that and his thoughts.

Bill Forbes

executive
#7

Appreciate that, Craig. It's Bill Forbes here. Right, so as it stands, the package insert we have permits periarticular administration providing as much as 72 hours of pain relief in cases of bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty. What we're putting forward through the sNDA is a move toward postsurgical analgesia covering soft tissue and orthopedic settings. Let me perhaps pull back a moment and speak in general terms about the vision established here at Heron. ZYNRELEF, in fact, has been examined across 14 clinical trials. Those 14 trials drew from 8 distinct surgical procedures: 4 involving soft tissue and 4 separate orthopedic surgical procedures. So the supplement was submitted, and it came in with data drawn from lumbar biosurgery, total shoulder surgery, mammoplasty, C-section, abdominoplasty. The lumbar spinal surgery and total surgery data have, in fact, already been shown at Western and Southern ortho conferences. That information is therefore already out in the public domain. And in a number of ways, I believe this will expand our label. With luck, we can work out a favorable label expansion using this data. Let me say a bit about what occurred regarding the major amendment. We had been conducting, and continue to conduct, certain studies, some of them preclinical, and we were running a rabbit study that looked somewhat further out. That one concerned intra-articular injection. As I've said previously, ZYNRELEF's indication is in fact periarticular, not intra-articular; thus the label itself warns physicians regarding using it intra-articularly. And from that angle, I think we view this as class labeling. This specific rabbit study merely looked somewhat further out, so although it's new data, it isn't truly a new finding and it's already reflected in our label; so I'd say that was somewhat of a letdown on our end; we didn't believe it was — it required — that the agency or the division had to declare a major amendment or — to this particular filing on account of that. So with luck, that addresses your question.

Boris Peaker

analyst
#8

I've got two things to ask. Starting with profitability — Craig, I'm simply wondering whether Heron could turn into a profitable company on the strength of supportive care by itself. Say we set ZYNRELEF aside: could the business be restructured so that it reaches profitability without ZYNRELEF?

Craig Collard

executive
#9

That isn't a lens we've actually used; though, once more, what you're describing is a scenario where we direct all of our attention toward APONVIE and give ZYNRELEF no promotional support whatsoever — in that case, clearly we'd run into inventory issues and similar problems, I'd imagine. Still, we haven't run that kind of analysis. That said, we aren't chasing exceptional growth or anything of that sort from ZYNRELEF. When it comes to profitability, we're simply letting the product follow the growth path it's already on. So once more, I believe some upside exists there. And likewise, we've stayed rather cautious with APONVIE; and I'd say one thing that surprised us is how strong our results continue to be with CINVANTI. So I think there's an upside in this that we haven't factored in. Yet I believe the core message we've worked hard to get across is this: we wanted transparency around the fact that we're working to divide this business and implement cost cuts that let us reach profitability, while keeping our outlook reasonably conservative.

Boris Peaker

analyst
#10

All right, and turning to ZYNRELEF in particular, then. Clearly you've discussed the 3 approved indications and how the label could be broadened later on. Yet among those indications already cleared, can you tell where revenue is originating at present? I'm just attempting to grasp better why it gets adopted in some places and not in others.

Craig Collard

executive
#11

Yeah. What I'd say is that our greatest traction so far has genuinely come in knee and hip. That is, after all, where most of the procedures take place. And once more, after those hospitals or ASCs move beyond, you know, the prep hurdle, the data we're seeing indicates that following roughly 4 months of use, we generally retain those accounts; so that's the area where we've enjoyed the strongest results until now.

Carl Byrnes

analyst
#12

Nice work on the momentum. Do you have any ideas regarding ZYNRELEF when it comes to a possible partnership? And how would that appear in terms of speeding things up and making the most of the sales team you already have? Then I also have something else to ask.

Craig Collard

executive
#13

Thanks, Carl. My apologies — we nearly disconnected you there. So, yes, one item we've been pursuing is what else can be done beyond the approaches already employed for making ZYNRELEF better, such as better targeting, utilizing improved data, positioning our reps, getting the most out of each territory, and so forth. We have been exploring ways to bring in a partner for this product. What troubles ZYNRELEF most isn't its clinical narrative. The genuine 72-hour pain relief matters a great deal. And when we examine market research and similar inputs, that area appears to — we see no problem at all there. I believe we've achieved quite strong results. The trouble lies in how the product gets prepared inside the surgical suite. That problem involves the nonsterile setting, plus simply how long it takes to draw the product from the bottle. So we've been evaluating several surgical firms that could serve as distributors, so to speak, and that we might partner with, ones essentially present in those surgical suites every day. I'm aware certain competitors have taken that route. We believe that by pushing harder within the surgical suite, our reps would be able to, first, devote more time to physicians explaining the product, and second, gain some freedom to handle other tasks involving APONVIE and CINVANTI. And the second benefit would be providing a boost to those products too. So I expect that within a relatively brief window, we'll select some kind of partner that expands our footprint with ZYNRELEF, and I think it ought to come from the low side of the product. Once more, these are items we have not forecasted.

Carl Byrnes

analyst
#14

Understood. Now let's shift topics a bit. Looking at SG&A, which I believe sits at roughly $36.4 million, and R&D at $17.6 million, could you break down how much during the quarter stemmed from severance and possibly one-time unusual charges, and what expense levels do you anticipate if you're able to comp out for the third quarter? Or if that isn't feasible — do you anticipate further one-time severance and one-time charges impacting the third quarter?

Ira Duarte

executive
#15

Yes. We — I believe we made public that we have roughly $5.9 million in a one-time charge that will flow through until the close of this year. So heading into 2024, you'll observe our operating expenses, a bounce settling at $120 million for the year, $120 million in 2024; and we think we can remove an additional $10 million from that moving forward.

Yuxi Dong

analyst
#16

Kelly couldn't join, so this is Clara filling in. Two things I'd like to ask. Regarding APONVIE, we've just completed the initial quarter where it's been selling. It sounds as though doctors have given you plenty of encouraging responses. I'm curious how we ought to view the path of revenue expansion moving forward for APONVIE.

Craig Collard

executive
#17

Yeah. That's a really good question, and honestly we've only had a limited amount of experience with APONVIE so far. The key distinction between APONVIE and ZYNRELEF comes down to this: whenever we land an IDN or a formulary victory for ZYNRELEF, a substantial amount of additional effort is still required with each individual surgeon and similar stakeholders; a systemwide switch doesn't automatically follow. With APONVIE, the contrast is that certain circumstances allow us to achieve conversion across an entire system. To put that more plainly, imagine a hospital network such as Baylor — if we could target moderate-to-severe patients specifically, we'd be able to reach essentially every one of them, meaning all the high-risk patients, and perhaps under those conditions they move over to APONVIE along with the Epic system and similar platforms; the result is a system-level victory that produces what you might call a conversion. Consequently, I believe what you'll observe across the coming quarters is that we start receiving systemwide orders generating larger revenue streams — practically like annuities, so to speak — within particular accounts as we move ahead. Up to now, a small number of hospital networks have made the switch. The results haven't truly reflected that yet, though that will start to change. Also, I believe 23 additional systems are currently under review at this moment. So once more, the progress genuinely pleases us. Clearly, a bit more time will be needed before those results become visible. Still, I'd say within a very brief window, you should start witnessing more of these larger orders, so to speak, coming in. And in the best case, our aim as we continue reporting is to offer slightly greater detail regarding hospital wins in the pipeline and similar matters. That approach would give us somewhat more transparency about what's genuinely happening with the product.

Yuxi Dong

analyst
#18

Thanks. I'm also wondering about ZYNRELEF — have you gotten varying feedback from physicians regarding its use across surgical indications? And knowing it may be on the market by the middle of 2024, how fast do you expect the sales growth curve to shift once VAN rolls out? What steps are you taking now, before that release, to boost sales?

Craig Collard

executive
#19

Yeah. From a scheduling standpoint, the positive side is that VAN remains on schedule. Our expectation is to launch it around the midpoint of next year. Two benefits come with it. First, it addresses the sterility problem and makes that far less complicated. Second, the duration required to administer the product will shrink. Rather than taking 3 to 4 minutes, it may take as little as 20 to 30 seconds, potentially more. That should have a major effect on the product purely in terms of how easy it is to use. As I've said previously, we're exploring a possible partnership with a surgical partner in the operating room. That's one item, along with the expanded label and, ideally, a broader footprint, as we move toward VAN. Each of these should drive greater sales and stronger growth; however, I'll repeat that we haven't built any of that into our path to profitability — these would be incremental sales — so we're fairly at ease about it. And once more, from a scheduling standpoint, everything appears to be on schedule.

Craig Collard

executive
#20

Once more, I'd like to express gratitude to all of you; this marks earnings call number 2 for us, yet your time and patience truly mean a lot. In my view, the company is achieving progress on its transformation; a bit of time will be required, though we are moving closer; and I believe several notable developments occurred during this quarter. Therefore, we're eager to share an update with everybody next quarter. Thanks.

Operator

operator
#21

Everyone, that brings us to the end of today's conference call. We appreciate you joining us, and at this point you're free to disconnect. Farewell.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Heron Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Heron Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Heron Therapeutics, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.